|
|
Post by bigreg38 on Jul 10, 2016 22:41:08 GMT -5
Good stuff, but it's also worth noting that Technosphere may not be the only options being looked at as a possible delivery system
WO2013016754 A1
"The particles may be obtained and engineered into any known particle engineering system, such as but not limited by the following: Pulmosphere™ or Pulmosol™ technology developed by Nektar, AIR™ porous particle technology develed by Alkermes, Technosphere™ technology developed by Mannkind, Powderhale™ technology developed by Vectura, particles created by Prosonix sonocrystalisation methods, particles created by wet or dry nano-milling technologies for example developed by Elan, Hovione or Savara."
|
|
|
|
Post by peppy on Jul 10, 2016 22:53:09 GMT -5
Have you all noticed the API for Receptor Life Sciences? Unless receptor life is looking to make oxytocin from cannabis, I think we are barking up the wrong tree. Just the facts.
IC 005. US 006 018 044 046 051 052. G & S: pharmaceutical preparations for human use; inhalers sold pre-filled with pharmaceutical preparations; plant extracts for pharmaceutical purposes
IC 042. US 100 101. G & S: scientific and medical research relating to the diagnosis and treatment of medical conditions; scientific and medical research relating to plant extracts for pharmaceutical purposes
IC 044. US 100 101. G & S: providing a website featuring information relating to the diagnosis and treatment of medical conditions
Though not definitive, this is support for claims that the API is some sort of cannabis extract.
Read more: mnkd.proboards.com/thread/4988/receptor-life-science#ixzz4E4IwKNi
|
|
|
|
Post by kc on Jul 11, 2016 0:04:53 GMT -5
Good stuff, but it's also worth noting that Technosphere may not be the only options being looked at as a possible delivery system WO2013016754 A1 "The particles may be obtained and engineered into any known particle engineering system, such as but not limited by the following: Pulmosphere™ or Pulmosol™ technology developed by Nektar, AIR™ porous particle technology develed by Alkermes, Technosphere™ technology developed by Mannkind, Powderhale™ technology developed by Vectura, particles created by Prosonix sonocrystalisation methods, particles created by wet or dry nano-milling technologies for example developed by Elan, Hovione or Savara." i just just want to hear how this is tied to the Gates foundation. Robin Offord and Monash university hopefully will unveil the linkage July 28, 2016 at the Reagan Center in Washington DC . Who is there industrial partner M. |
|
|
|
Post by mnholdem on Jul 11, 2016 9:26:25 GMT -5
Good stuff, but it's also worth noting that Technosphere may not be the only options being looked at as a possible delivery system WO2013016754 A1 "The particles may be obtained and engineered into any known particle engineering system, such as but not limited by the following: Pulmosphere™ or Pulmosol™ technology developed by Nektar, AIR™ porous particle technology develed by Alkermes, Technosphere™ technology developed by Mannkind, Powderhale™ technology developed by Vectura, particles created by Prosonix sonocrystalisation methods, particles created by wet or dry nano-milling technologies for example developed by Elan, Hovione or Savara." i just just want to hear how this is tied to the Gates foundation. Robin Offord and Monash university hopefully will unveil the linkage July 28, 2016 at the Reagan Center in Washington DC . Who is there industrial partner M. We already know that Mintaka was working with MannKind Corporation to develop an inhalable oxytocin. At the the Bill & Melinda Gates Foundation website, you will find that Offord was recently (1-Jan-2016) awarded a grant:
Reduction of Maternal Death Through Postpartum Hemorrhage: A Highly Heat-Resistant Form of Oxytocin That Does Not Require Injection
Robin Offord,The Mintaka Foundation for Medical Research(Geneva, Switzerland)
Grand Challenges for Development | Saving Lives at Birth | 1 Jan 2016
Source: gcgh.grandchallenges.org/grants?items_per_page=10&combined_sort=field_funding_dates_value%20DESC&sort_order=DESC&sort_by=field_funding_dates_value&page=5
---
What is troubling me about his entire subject is that GSK recently completed a Phase I trial of their powdered oxytocin, but there has been no hint of any oxytocin trial(s) by either Mintaka or MannKind. Perhaps trials are planned (FDA/EMA) but if that's the case then Glaxo has a huge lead. 
|
|
|
|
Post by kbrion77 on Jul 11, 2016 9:35:07 GMT -5
i just just want to hear how this is tied to the Gates foundation. Robin Offord and Monash university hopefully will unveil the linkage July 28, 2016 at the Reagan Center in Washington DC . Who is there industrial partner M. We already know that Mintaka was working with MannKind Corporation to develop an inhalable oxytocin. At the the Bill & Melinda Gates Foundation website, you will find that Offord was recently (1-Jan-2016) awarded a grant:
Reduction of Maternal Death Through Postpartum Hemorrhage: A Highly Heat-Resistant Form of Oxytocin That Does Not Require Injection
Robin Offord,The Mintaka Foundation for Medical Research(Geneva, Switzerland)
Grand Challenges for Development | Saving Lives at Birth | 1 Jan 2016
Source: gcgh.grandchallenges.org/grants?items_per_page=10&combined_sort=field_funding_dates_value%20DESC&sort_order=DESC&sort_by=field_funding_dates_value&page=5
---
What is troubling me about his entire subject is that GSK recently completed a Phase I trial of their powdered oxytocin, but there has been no hint of any oxytocin trial(s) by either Mintaka or MannKind. Perhaps trials are planned (FDA/EMA) but if that's the case then Glaxo has a huge lead.
Well best we can hope for is some type of patent infringement from them lol. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 11, 2016 9:43:58 GMT -5
What is troubling me about his entire subject is that GSK recently completed a Phase I trial of their powdered oxytocin, but there has been no hint of any oxytocin trial(s) by either Mintaka or MannKind. Perhaps trials are planned (FDA/EMA) but if that's the case then Glaxo has a huge lead.
are they working in collaboration with GSK as developer? adisinsight.springer.com/drugs/800041333clinicaltrials.gov/ct2/show/NCT02542813 |
|
|
|
Post by kc on Jul 11, 2016 10:05:21 GMT -5
What is troubling me about his entire subject is that GSK recently completed a Phase I trial of their powdered oxytocin, but there has been no hint of any oxytocin trial(s) by either Mintaka or MannKind. Perhaps trials are planned (FDA/EMA) but if that's the case then Glaxo has a huge lead.
are they working in collaboration with GSK as developer? adisinsight.springer.com/drugs/800041333clinicaltrials.gov/ct2/show/NCT02542813It makes know sense to me either but when you watch and listen very carefully to Robin Offord's statement that the inhaler design is from "industrial partner" We see Monash hiding behind this statement on their twitter account.
So its a complete mystery. What is the name of the MannKind organization in Switzerland? Is that wholly owned by MannKind? Or is it a separate company unaffiliated?
The good thing is that Round Six competition is open to the public in Washington, DC on July 28th and a person in the DC area can register and go see the exhibition there. They can then ask that question directly and perhaps see and hold the device (technosphere) if it really is a MannKind Technosphere.
An RSVP is required to attend events throughout the day. Please register via the survey below.
We are narrowing our pool of innovators, and these finalists, along with our existing grantees, have been invited to the DevelopmentXChange in Washington, D.C., to participate in the final stage of the competition and actively network their ideas with businesses, funders, development experts, non-governmental organizations and each other.
When: 11:30am to 6:00pm July 28th 2016
Where: Ronald Reagan Building and International Trade Ctr
1300 Pennsylvania Avenue NW
Washington, DC 20004
Please complete the following fields to register to attend the 2016 Saving Lives at Birth DevelopmentXChange. The Pitch Competition will take place from 11:30am-4:00pm. The Marketplace and reception will take place from 4:00-6:00pm. Please note times are subject to change. Continue checking this page, and www.savinglivesatbirth.net, for updates www.surveygizmo.com/s3/2727482/2016-Saving-Lives-at-Birth-DevelopmentXChange-General-Registration
The Pitch Competition will take place from 11:30am-4:00pm. The Marketplace and reception will take place from 4:00-6:00pm.
MAYBE I HAVE THIS ALL WRONG AND MINTAKA IS IN COMPETION WITH OR AGAINST MONASH ON THE DEVELOPMENT OF INHALED OXYTOCIN?
|
|
|
|
Post by kbrion77 on Jul 11, 2016 10:12:46 GMT -5
What is troubling me about his entire subject is that GSK recently completed a Phase I trial of their powdered oxytocin, but there has been no hint of any oxytocin trial(s) by either Mintaka or MannKind. Perhaps trials are planned (FDA/EMA) but if that's the case then Glaxo has a huge lead.
are they working in collaboration with GSK as developer? adisinsight.springer.com/drugs/800041333clinicaltrials.gov/ct2/show/NCT02542813Doubtful. I think it's a race between Mannkind/Mintaka and GSK/Monash to who can develop the better inhaled oxytocin. I have spent 6 years of thinking Mannkind had all sorts of things going on behind the scenes and they were connected to everything so I've become a little pessimistic. Maybe we will learn further on the 28th from the DevelopmentXChange competition. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 11, 2016 10:12:49 GMT -5
www.mintakafoundation.org/our-projects/maternal-health/Many deaths by bleeding could be prevented by an immediate intravenous injection of the drug oxytocin. However, oxytocin is unstable in warm climates and trained staff are not always available to give injections. With MannKind Corporation (USA), we have formulated oxytocin in a dry, stabilized form which can be loaded into a robust, very inexpensive, disposable inhaler, eliminating at the same time the need for injection. Administration by inhalation at last makes treatment possible outside centres with trained medical staff.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 11, 2016 10:25:46 GMT -5
Maybe KC forced their hand into coughing up information? lol
|
|
|
|
Post by kc on Jul 11, 2016 10:31:13 GMT -5
Maybe KC forced their hand into coughing up information? lol Bad pun coughing up....lol.
But they posted on Youtube back in November 2015 A highly heat-resistant form of oxytocin that does not require injection ...
Video for mintaka foundation▶ 1:36
Nov 30, 2015 - Uploaded by SavingLivesGCD
Organization: The Mintaka Foundation for Medical Research Round 5 Grantee.
But I might have had this wrong and they are in competition against Monash and GSK?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 11, 2016 10:34:13 GMT -5
So is this new or old information from their website listing the partnership?
|
|
|
|
Post by brentie on Jul 11, 2016 10:50:48 GMT -5
|
|
|
|
Post by kbrion77 on Jul 11, 2016 10:58:10 GMT -5
Maybe KC forced their hand into coughing up information? lol Bad pun coughing up....lol.
But they posted on Youtube back in November 2015 A highly heat-resistant form of oxytocin that does not require injection ...
Video for mintaka foundation▶ 1:36
Nov 30, 2015 - Uploaded by SavingLivesGCD
Organization: The Mintaka Foundation for Medical Research Round 5 Grantee.
But I might have had this wrong and they are in competition against Monash and GSK?
Is it not as simple as Monash/GSK started the development for inhaled oxytocin back in 2011 and then in 2015 Mintaka/Mannkind partnering and believing they have a better formula and delivery system? |
|
|
|
Post by kc on Jul 11, 2016 10:58:35 GMT -5
|
|
